Notably, U18666A, an NPC1 inhibitor, significantly enhanced the therapeutic efficacy of conventional chemotherapy in established multiple myeloma (MM) and solid tumors, highlighting the potential for NPC1 inhibitors as promising novel chemotherapeutic agents. This evidence concerns the gene NPC1 and Miyoshi myopathy.